Enrollment Open for Phase 1/2 Study of Glioblastoma Drug
According to an article from Drugs.com, MediciNova Inc. has announced the first enrollment in its phase 1/2 clinical trial of MN-166, an experimental drug that hopes to target recurrent glioblastoma…